BAY-293

BAY-293 is the first drug reported to act as an inhibitor of the guanine nucleotide exchange factor protein SOS1. It acts by preventing SOS1 from binding to its target protein KRAS. It has potential applications in the treatment of cancer, and has been widely used in cancer research.^{[1][2][3][4][5]}

Drug classSOS1 inhibitor

CAS Number

• 2244904-70-7

PubChem CID

• 137322663

IUPHAR/BPS

• 10480

Quick facts Clinical data, Drug class ...

BAY-293

Clinical data
Drug class	SOS1 inhibitor
Identifiers
IUPAC name 6,7-dimethoxy-2-methyl-N-[(1R)-1-[4-[2-(methylaminomethyl)phenyl]thiophen-2-yl]ethyl]quinazolin-4-amine
CAS Number	2244904-70-7
PubChem CID	137322663
IUPHAR/BPS	10480
ChemSpider	72380155
ChEBI	CHEBI:232851
ChEMBL	ChEMBL4535474
PDB ligand	AXH (PDBe, RCSB PDB)
Chemical and physical data
Formula	C25H28N4O2S
Molar mass	448.59 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NC2=CC(=C(C=C2C(=N1)N[C@H](C)C3=CC(=CS3)C4=CC=CC=C4CNC)OC)OC
InChI InChI=1S/C25H28N4O2S/c1-15(24-10-18(14-32-24)19-9-7-6-8-17(19)13-26-3)27-25-20-11-22(30-4)23(31-5)12-21(20)28-16(2)29-25/h6-12,14-15,26H,13H2,1-5H3,(H,27,28,29)/t15-/m1/s1 Key:WEGLOYDTDILXDA-OAHLLOKOSA-N

Close